August 2024 FDA Recall Cefixime by Lupin Pharmaceuticals Inc. (D-0648-2024 - Subpotent Drug- An out of specification ( OOS ) result observed in assay test during 18-month long term stability study.)

This Class II drug recall was voluntarily initiated by Lupin Pharmaceuticals Inc. on August 21, 2024 for the product Cefixime. The FDA reported the reason for recall as subpotent drug- an out of specification ( oos ) result observed in assay test during 18-month long term stability study.. The product was distributed Nationwide and the recall is currently terminated.

Recall Number: D-0648-2024

Reason for Recall
Subpotent Drug- An out of specification ( OOS ) result observed in assay test during 18-month long term stability study.
Initiated
08-21-2024
Reported
09-04-2024
Quantity
4554 bottles

Recall Profile & Regulatory Data

Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Lupin Pharmaceuticals Inc.
Cefixime for Oral Suspension USP, 100 mg/5 mL, 50 mL bottle, Rx only, Manufactured for: Lupin Pharmaceuticals, Inc., Baltimore, Maryland 21202, Manufactured by: Lupin Limited, Mandideep 462 046 INDIA, NDC 68180-405-01

Batch or Lot Expiration Information

Lot# : F201517, Exp 11/30/2024